skip navigation


Register for Latest Research

Stay Informed
Register with NCJRS to receive NCJRS's biweekly e-newsletter JUSTINFO and additional periodic emails from NCJRS and the NCJRS federal sponsors that highlight the latest research published or sponsored by the Office of Justice Programs.

NCJRS Abstract

The document referenced below is part of the NCJRS Virtual Library collection. To conduct further searches of the collection, visit the Virtual Library. See the Obtain Documents page for direction on how to access resources online, via mail, through interlibrary loans, or in a local library.


NCJ Number: 228920 Find in a Library
Title: Substance Use and the Treatment of Resistant Depression in Adolescents
Journal: Journal of the American Academy of Child & Adolescent Psychiatry  Volume:48  Issue:12  Dated:December 2009  Pages:1182-1192
Author(s): Benjamin I. Goldstein, M.D., Ph.D.; Wael Shamseddeen, M.D.; Anthony Spirito, Ph.D.; Graham Emslie, M.D.; Greg Clarke, Ph.D.; Karen Dineen Wagner, M.D., Ph.D.; Joan Rosenbaum Asarnow, Ph.D.; Benedetto Vitiello, M.D.; Neal Ryan, M.D.; Boris Birmaher, M.D.; Taryn Mayes, M.S.; Matthew Onorato, L.C.S.W.; Jamie Zelazny, M.P.H., R.N.; David A. Brent, M.D.
Date Published: December 2009
Page Count: 11
Sponsoring Agency: National Institute of Mental Health
Bethesda, MD 20852
Grant Number: MH61835;MH61856;MH61864, MH61869;MH61958;MH62014;
Type: Report (Study/Research)
Format: Article
Language: English
Country: United States of America
Annotation: This study examined issues related to the treatment of adolescents with co-occurring major depressive disorder (MDD) and substance use disorder.
Abstract: The study found that, overall substance use was common among adolescents with treatment-resistant MDD. The subjects who had persistently low substance-related impairment or who showed reduced substance-related impairment had better MDD treatment response, although the direction of this association was uncertain. The study found that 28.1 percent of the 334 adolescents with MDD reported repeated experimentation with substance use at baseline. In addition, substance-related impairment was associated with baseline depression severity, older age, physical/sexual abuse, family conflict, hopelessness, and comorbid oppositional defiant disorder/conduct disorder. Among the adolescents who responded to treatment for MDD, there was significant improvement in substance-related impairment. The treatment response for MDD was best among the adolescents with low 12-week substance-related impairment scores regardless of whether they had high or low baseline substance-related impairments. Baseline suicidal ideation was higher among the youth who progressed to high substance-related impairment compared with those whose substance-related impairment remained low; and parental depressive symptoms predicted the persistence of high substance-related impairment during the study. Treatment types (i.e., pharmacological or cognitive-behavioral therapy) had no significant differential effects on substance use. The 334 participating youth were enrolled in the Treatment of SSRI-Resistant Depression in Adolescents trial. SSRI refers to selective serotonin reuptake inhibitors, which are used in treating adults with comorbid MDD and SUD. Analyses examined substance use with the Drug Use Severity Index and changes in substance use in relation to treatment and depressive symptoms. 4 tables and 43 references
Main Term(s): Juvenile mental health services
Index Term(s): Childhood depression; Juvenile drug use; Juvenile suicide; Treatment effectiveness
To cite this abstract, use the following link:

*A link to the full-text document is provided whenever possible. For documents not available online, a link to the publisher's website is provided. Tell us how you use the NCJRS Library and Abstracts Database - send us your feedback.